FY2026 EPS Estimate for SCYNEXIS Reduced by Analyst

SCYNEXIS, Inc. (NASDAQ:SCYX) – Equities research analysts at Brookline Capital Acquisition decreased their FY2026 earnings per share (EPS) estimates for shares of SCYNEXIS in a note issued to investors on Monday, March 9th. Brookline Capital Acquisition analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.34) for the year, down from their previous forecast of $1.03. Brookline Capital Acquisition has a “Buy” rating on the stock. Brookline Capital Acquisition also issued estimates for SCYNEXIS’s FY2027 earnings at ($0.20) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at ($0.62) EPS.

SCYX has been the subject of several other research reports. Wall Street Zen upgraded shares of SCYNEXIS from a “hold” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SCYNEXIS in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SCYNEXIS has a consensus rating of “Hold” and an average target price of $3.00.

SCYNEXIS Price Performance

SCYNEXIS stock opened at $0.89 on Thursday. The stock’s 50 day moving average is $0.74 and its 200 day moving average is $0.75. SCYNEXIS has a one year low of $0.57 and a one year high of $1.31. The firm has a market cap of $39.84 million, a P/E ratio of -5.25 and a beta of 1.33.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings results on Wednesday, March 4th. The company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.04). SCYNEXIS had a negative net margin of 41.79% and a negative return on equity of 25.52%. The company had revenue of $17.20 million during the quarter, compared to the consensus estimate of $8.10 million.

Institutional Trading of SCYNEXIS

Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of SCYNEXIS during the 2nd quarter valued at $27,000. Bridgeway Capital Management LLC grew its holdings in SCYNEXIS by 4.2% in the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after purchasing an additional 14,689 shares during the period. Sequoia Financial Advisors LLC bought a new stake in SCYNEXIS in the third quarter valued at $41,000. Vanguard Group Inc. increased its stake in SCYNEXIS by 6.4% in the third quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock valued at $1,357,000 after purchasing an additional 105,600 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of SCYNEXIS by 95.2% during the third quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock valued at $80,000 after purchasing an additional 50,916 shares during the period. Institutional investors and hedge funds own 54.37% of the company’s stock.

Trending Headlines about SCYNEXIS

Here are the key news stories impacting SCYNEXIS this week:

• Positive Sentiment: Brookline raised multi‑year estimates and keeps a Buy — The firm improved FY2027, FY2028 and FY2029 EPS projections (FY2027 to ($0.20) from ($0.48); FY2028 to ($0.29) from ($0.30); FY2029 to ($0.62) from ($0.64)) and continues to rate SCYNEXIS a “Buy.” These upward tweaks for later-year estimates may support a more constructive medium-term story for the stock.
• Positive Sentiment: Clinical progress — First participants dosed in the Phase 1 single-ascending and multiple-ascending dose trial of IV SCY-247, SCYNEXIS’s second‑generation triterpenoid antifungal. Early clinical milestones reduce binary trial risk in the near term and can be a catalyst if safety and PK readouts are positive. Phase 1 dosing announcement
• Neutral Sentiment: Quarterly & long‑range forecasts published — Brookline released Q1–Q4 2026 quarterly EPS estimates (generally around ($0.10) per quarter, Q4 at ($0.05)) and a FY2030 projection of $0.46 EPS. These provide a structured roadmap for expectations but are distant and depend on pipeline progress and financing, so impact is uncertain.
• Negative Sentiment: Material near‑term cut for FY2026 — Brookline sharply reduced its FY2026 EPS forecast to ($0.34) from a prior $1.03. That large downward revision signals a weaker near-term profitability/cash-flow outlook than previously modeled and likely explains downward pressure on the stock today.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.